Entrada Therapeutics has faced a significant setback in its pursuit to develop a treatment for Duchenne muscular dystrophy (DMD), resulting in a dramatic drop in the company’s stock value. The Boston-based biotech released phase 1/2 data for its exon 44 skipping drug candidate, ENTR-601-44, revealing a mere 2.36% increase in dystrophin production over a baseline of 4% among the initial cohort of patients. This outcome starkly contrasts with earlier expectations from both analysts and Entrada executives.
In January, during the J.P. Morgan Healthcare Conference, CEO Dipal Doshi expressed strong confidence in the efficacy of ENTR-601-44, anticipating double-digit dystrophin levels. He indicated that the company aimed to surpass the results of its main competitor, Avidity Biosciences, which is developing a rival candidate, delpacibart zotadirsen (del-zota). At that time, del-zota had demonstrated a 25% increase in dystrophin production in patient trials, further adding to the competitive landscape.
Market analysts from Guggenheim Securities had previously estimated that for Entrada to remain competitive, it would need to report between 10% and 14% dystrophin restoration, predicting a 60% likelihood of achieving this target. Conversely, they assigned a 20% likelihood to single-digit results, forecasting a possible halving of Entrada’s stock price if that scenario played out. Their predictions proved accurate, with Entrada’s shares plummeting 59% to $6.57 upon market opening Thursday, a sharp decline from the previous day’s closing price of $16.02.
In light of the underwhelming readout, analysts who had labeled the data as a “platform-validating readout” declared that Entrada needed to revisit its strategy. The company is expected to provide further insights from a higher-dose cohort scheduled for the fourth quarter, which may clarify whether ENTR-601-44 can recover from this downturn.
Entrada’s management pointed to reduced plasma exposure in juvenile DMD patients as a key factor in the disappointing results. The exposure levels were found to be approximately 50% lower than those in healthy adults and nonhuman primates (NHPs). This unexpected data prompted Doshi to reflect on recent findings from juvenile NHP studies, which revealed a similar trend. According to Natarajan Sethuraman, Ph.D., president of R&D at Entrada, this suggests a “steep, nonlinear exon skipping response” at elevated plasma levels, indicating that subsequent dosing could yield significantly improved exon skipping outcomes.
The company is also planning to investigate a third dosing cohort, potentially providing further opportunities to refine its approach to treating DMD. The path forward will hinge on the results of upcoming trials and whether ENTR-601-44 can rebound from these disappointing early findings.
